Urologic Oncology-Seminars and Original Investigations

Papers
(The median citation count of Urologic Oncology-Seminars and Original Investigations is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Festschrift essay to celebrate Dr. Michael Droller54
Cover 2 - Masthead44
Genetic variations related to the prostate cancer risk: A field synopsis and revaluation by Bayesian approaches of genome-wide association studies39
PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors39
GROWTH OF VON HIPPEL-LINDAU (VHL)-ASSOCIATED RENAL TUMORS DURING PREGNANCY36
UTILITY OF C-REACTIVE PROTEIN LEVELS IN IMPROVING RISK STRATIFICATION IN METASTATIC RENAL CELL CARCINOMA34
A QUALITATIVE EXPLORATION OF THE EXPERIENCE OF TRANSGENDER AND GENDER NONCONFORMING PATIENTS WITH GENITOURINARY AND GYNECOLOGIC MALIGNANCIES33
Extracellular vesicles in renal cell carcinoma: A review of the current landscape and future directions32
Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database32
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy31
Salvage local treatment for recurrent prostate cancer after focal therapy: A systematic review and meta-analysis31
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy31
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma30
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy30
National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy29
The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients27
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collabor27
Methodological considerations for systematic review and meta-analysis of Xpert bladder cancer monitor26
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer25
Is YouTube a good resource for patients to better understand kidney cancer?25
Carbonic anhydrase 10 functions as a tumor suppressor in renal cell carcinoma and its methylation is a risk factor for survival outcome25
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer24
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens24
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?24
Guideline discordant care in patients with metastatic germ cell tumors24
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites23
Editorial Board23
Managing female sexual dysfunction23
Predictors of discharge to home following major surgery for urologic malignancies: Results from the national surgical quality improvement program22
Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients22
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs22
APPLICATION OF THE STRATCANS CRITERIA TO THE MUSIC AS COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE21
NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY21
PREVALENCE OF OCCULT UROLOGIC MALIGNANCIES IN PATIENTS UNDERGOING SCREENING FOR LUNG CANCER21
DECIPHER® GENOMIC CLASSIFIER SCORE ON INITIAL BIOPSY IS ASSOCIATED WITH PROGRESSION FORM ACTIVE SURVEILLANCE TO TREATMENT IN PROSTATE CANCER21
PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES21
Editorial Board20
REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST20
Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns20
“Published abstracts from the 24th Annual Meeting of the Society of Urologic Oncology”20
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-320
COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION20
Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study19
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study19
Multicenter study of active surveillance for small renal masses: Real world practice pattern19
Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma19
Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma18
Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma: A multi-institutional study18
Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients18
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-0218
TUMOROID AND GENOMIC MODELING OF LOW GRADE INTERMEDIATE RISK BLADDER CANCER TO PREDICT INTRAVESICAL CHEMOTHERAPY RESPONSE18
The centralization of bladder cancer care and its implications for patient travel distance18
Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset18
Prospective validation of clino-radio-pathological risk scoring system (CRiSS) for prediction of inguinal lymph-nodes metastasis in squamous cell carcinoma of penis17
AUTOMATED NEPHROMETRY SCORES THROUGH DIRECT PREDICTION OF EACH COMPONENT17
CLINICAL PROGRESSION OF PROSTATE CANCER FROM ACTIVE SURVEILLANCE IS PREDICTED BY DECIPHER® GENOMIC CLASSIFIER SCORE ON INDEX BIOPSY INDEPENDENT FROM RISK ASSESSMENT BY MRI CHARACTERISTICS17
Multivariate analysis of the parameters affecting the choice of surgical treatment for patients with localized renal cell carcinoma (RCC)17
FACTORS ASSOCIATED WITH PROSTATE CANCER SCREENING AMONG HISPANIC MEN: RESULTS FROM HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL)17
Diagnostic performance of 68Ga-PSMA-11 PET/MRI in biochemical recurrent prostate cancer after radical prostatectomy and prediction nomogram17
IMMEDIATE LYMPHATIC RECONSTRUCTION WITH LYMPHATICOVENOUS BYPASS CREATION AFTER BILATERAL INGUINAL LYMPH NODE DISSECTION FOR PENILE CANCER: A CASE SERIES17
Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance17
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank16
Nivolumab plus gemcitabine–cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial16
Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non–muscle invasive bladder cancer16
Assessing the sex-based enrollment gap in urologic oncology clinical trials16
Morbidity and mortality of salvage radical prostatectomy for prostate cancer: An analysis of the National surgical quality improvement program targeted prostatectomy database16
Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma16
Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients16
A polygenic risk score is associated with risk of bladder cancer and earlier age of diagnosis, independent of lifestyle factors16
Exploring the tumor-promoting function and prognostic value of ESPL1 in prostate adenocarcinoma16
The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: An analysis of the ROBUUST 2.0 registry16
Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities15
Prospective validation of the Kaiser Permanente prostate cancer risk calculator in a contemporary, racially diverse, referral population15
Multimodality treatment of penile cancer: Part 215
Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prosp15
Impact of the time elapsed between prostate biopsy and surgery on the accuracy of nomograms predicting lymph node invasion in patients with clinically localized prostate cancer14
EDARADD silencing suppresses the proliferation and migration of bladder cancer cells14
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis14
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity14
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma14
Number of cores needed to diagnose prostate cancer during MRI targeted biopsy decreases after the learning curve14
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)14
Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data14
IMPACT OF NODAL DISEASE IN NON-CLEAR CELL RENAL CELL CARCINOMA AND THE ROLE OF SALVAGE LYMPH NODE RESECTION13
Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer13
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor13
Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy13
PSYCHOLOGICAL RESILIENCE AND DISTRESS AMONG RADICAL CYSTECTOMY PATIENTS: A SYMPTOM DISTRESS SCALE SURVEY ANALYSIS13
Conditional survival of stage III non-seminoma testis cancer patients13
Comparison of microwave ablation and partial nephrectomy for T1a small renal masses13
UTILIZING LOW-PASS WHOLE GENOME SEQUENCING OF URINARY-TUMOR DNA TO IDENTIFY MINIMAL RESIDUAL DISEASE PRIOR TO REPEAT TRANSURETHRAL RESECTION OF BLADDER TUMOR13
RETROPERITONEAL NODAL DISTRIBUTION OF METASTATIC SEMINOMA: A CLINICAL MAPPING STUDY13
Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma13
FEASIBILITY AND OUTCOMES OF INTERVENTIONS TO REDUCE CYSTOSCOPY DISCOMFORT: A QUALITY IMPROVEMENT PILOT13
Editorial Board12
Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancer12
Cover 2 - Masthead12
Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus12
COMPARING WHITE LIGHT VERSUS BLUE LIGHT CYSTOSCOPY RECURRENCE OUTCOMES AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS12
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety12
Prostate magnetic resonance imaging utilization and its relationship with advanced prostate cancer detection12
Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review12
Commentary on: “Adjuvant vs. salvage radiotherapy in men with pathologically node-positive prostate cancer after radical prostatectomy”12
INTENSIFIED MRI-BASED PROSTATE CANCER SCREENING IN GERMLINE CARRIERS OF RARE PATHOGENIC VARIANTS: INTERIM RESULTS FROM THE INITIAL SCREENING ROUND OF THE PROGRESS STUDY12
CHEST CT SHOULD REPLACE CHEST X-RAYS TO EVALUATE FOR THORACIC RENAL CELL CARCINOMA METASTASES12
A comparison of outcomes between transperitoneal and retroperitoneal robotic assisted partial nephrectomy in patients with completely endophytic kidney tumors12
Pathologic and Short-Term Oncologic Outcomes of Prostate Cancer Patients Following Transvesical Robot-Assisted Radical Prostatectomy12
Masculinity stigma and metastatic prostate cancer: A review with a focus on Latin America12
SURVIVAL PATTERNS BASED ON SITE-SPECIFIC VISCERAL METASTASIS IN METASTATIC PROSTATE CANCER PATIENTS: ARE OUTCOMES OF VISCERAL METASTASES THE SAME?12
MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: SINGLE INSTITUTION EXPERIENCE OF TREATMENT EFFICACY12
DEFINING THE IMPACT OF PERSONAL AND FAMILY HISTORY OF LYNCH-SYNDROME ASSOCIATED CANCERS ON CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA12
Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?12
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy12
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET11
PSMA PET/CT-DETECTED MESORECTAL LYMPH NODE METASTASES: TREATMENT OUTCOMES AND CLINICAL IMPLICATIONS11
Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma11
Contemporary outcomes for robotic radical cystectomy and intracorporeal neobladder urinary diversion11
Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons11
Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection11
LARGE LANGUAGE MODEL FOR PROVIDING PATIENT-FOCUSED GUIDANCE FOLLOWING RADICAL PROSTATECTOMY11
State of the Art: The Microbiome in Bladder Cancer11
LOW-GRADE AND HIGH-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RESPOND DIFFERENTLY TO BACILLUS CALMETTE-GUÉRIN AND GEMCITABINE-DOCETAXEL11
HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center11
Opioid prescription following radical orchiectomy associated with new persistent opioid use11
2024 Star Reviewers for Urologic Oncology11
Table of Contents11
CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING FOLLOWING THE 2018 UNITED STATES PREVENTIVE SERVICES TASK FORCE GUIDELINES AND THROUGH THE COVID-19 PANDEMIC11
BLOOD-BASED LIQUID BIOPSY IN DIAGNOSIS, SURVEILLANCE, AND PROGNOSIS OF PATIENTS WITH PRIMARY UPPER TRACT UROTHELIAL CARCINOMA11
Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma11
Evaluation of short term surgical outcomes of radical prostatectomy in the decade following the introduction of minimum volume standards in the Netherlands11
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy11
PHASE 3 MK-5684-004 STUDY OF CYP11A1 INHIBITOR OPEVESOSTAT VERSUS NEXT-GENERATION HORMONAL AGENT (NHA) SWITCH IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER 1 PRIOR NHA11
Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy11
Characteristics Contributing to Survival Differences Between Black and White Patients Following Cystectomy11
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma11
Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis11
Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry11
Editorial Board10
The effect of race on stage at presentation and survival in upper tract urothelial carcinoma10
The 5-item frailty index predicts 30-day morbidity and mortality in radical nephrectomy patients: A propensity matched analysis10
Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer10
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center10
Mutational landscape of non-muscle-invasive bladder cancer10
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide10
Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida10
Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma10
Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients10
Cover 2 - Masthead10
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention10
Association of heavy metals and trace elements in renal cell carcinoma: A case-controlled study10
Bilateral inguinal lymphadenectomy using simultaneous double laparoscopies for penile cancer: A retrospective study10
Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer10
Device-related complications during renal cryoablation: insights from the Manufacturer and User Facility Device Experience (MAUDE) database10
Development of a specific supportive care needs scale for radical cystectomy patients and its reliability and validity test10
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database10
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients10
HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY OR OTHER SUBTYPES NOT A PREDICTOR FOR PROGRESSION IN BCG-TREATED PATIENTS9
A machine learning approach to predict progression on active surveillance for prostate cancer9
Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study9
EARLY POSTOPERATIVE CANCER-SPECIFIC DEATH AMONGST PATIENTS WITH HIGH-RISK NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA: REFINING RISK STRATIFICATION TO OPTIMIZE SELECTION FOR ADJUVANT THERAPY9
INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE F9
LEVEL OF NODAL METASTASIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY AND LYMPHADENECTOMY: IS THERE A ROLE OF EXTENDED LYMPHADENECTOMY IN THE POST-S1011 ERA?9
Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence9
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer9
Editorial Board9
Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC9
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential9
The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis9
Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysis9
INTRAVESICAL AUTOLOGOUS TIL THERAPY IN BCG-EXPOSED NMIBC: A REPORT OF EARLY SAFETY AND EFFICACY FINDINGS9
THE NONCANONICAL WNT PATHWAY (FYN/STAT3) ACTIVATED BY YY1 PROMOTES THE NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER CELLS.9
MAPPING PATTERNS OF RECURRENCE AFTER SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER9
2023 Star Reviewers for Urologic Oncology9
THE PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOR DNA IN PATIENTS WITH POSITIVE LYMPH NODE DISEASE AFTER ROBOTIC-ASSISTED RADICAL CYSTECTOMY9
Thermal ablation for local tumor recurrence after previous partial nephrectomy: Perioperative and oncological outcomes9
THE ASSOCIATION BETWEEN HEALTH LITERACY AND ALL-CAUSE MORTALITY IN UROLOGIC CANCER PATIENTS9
Annular-shaped stenosis in the ureter: Caution should be taken9
“I was in a very deep, dark place... I wasn't prepared for that”: A qualitative assessment of the emotional well-being needs of patients undergoing cystectomy9
THE PROGNOSTIC ROLE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH INTRAVESICAL GEMCITABINE AND DOCETAXEL9
A PHASE IIB RANDOMIZED PLACEBO-CONTROLLED TRIAL TESTING A LONG-CHAIN OMEGA-3 FATTY ACID MAG-EPA DIETARY SUPPLEMENT ON PROSTATE CANCER AND GUT MICROBIOME9
QUANTIFYING THE BENEFIT OF SALVAGE RADIATION THERAPY FOR BIOCHEMICALLY RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY9
The role of autophagy dysregulation in low and high-grade nonmuscle invasive bladder cancer: A survival analysis and clinicopathological association9
Clinically significant prostate cancer detection rate in biopsy-naïve patients with mpMRI and microultrasound topographically discordant lesions: A single-center retrospective analysis9
Development of point-of-care tests for urinary bladder cancer – an historic review and view to future prospectives9
STIMULATED RAMAN HISTOLOGY AND ARTIFICIAL INTELLIGENCE ALLOWS FOR PREDICTION OF PROSTATE CANCER EXTRAPROSTATIC EXTENSION AND POSITIVE SURGICAL MARGIN DURING RADICAL PROSTECTOMY8
Avoiding “Needless” nephrectomy: What is the role of small renal mass biopsy in 2024?8
Liquid biopsy testing in urological cancers: Focus on urine8
Deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: A systematic review and patient-level meta-analysis8
Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system8
Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy databa8
PIVOT-006: A PHASE 3, RANDOMIZED STUDY OF ADJUVANT INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC VERSUS SURVEILLANCE FOR THE TREATMENT OF INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER8
GRADE AND VOLUME PROGRESSION AND ITS ASSOCIATION WITH THE DECIPHER GENOMIC CLASSIFIER USING PATIENTS ENROLLED IN A PROSPECTIVE ACTIVE SURVEILLANCE PROTOCOL8
Cover 2 - Masthead8
ONCOLOGIC OUTCOMES OF BLADDER-SPARING MANAGEMENT FOR HIGH-GRADE NON-INVASIVE UROTHELIAL CARCINOMA OF THE PROSTATIC URETHRA8
Transperineal 3T MRI-guided and transrectal MRI-ultrasound fusion prostate biopsies: Do lesion location and size impact diagnostic yield?8
Artificial intelligence in prostate cancer: Definitions, current research, and future directions8
THE DISPARITY OF LYMPH NODE DISSECTION IN T2+N0M0 STAGE PENILE SQUAMOUS CELL CARCINOMA PATIENTS8
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment8
Table of Contents8
Predictive factors for recurrence and outcomes in T1a renal cell carcinoma: Analysis of the INMARC (International Marker Consortium for Renal Cancer) database8
Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort8
Rates of volume reduction after selective arterial embolization for renal angiomyolipoma8
EARLY ONCOLOGIC OUTCOME AND PSA KINETICS FOLLOWING IRREVERSIBLE ELECTROPORATION IN MEN WITH PROSTATE CANCER8
COMPARING ACTIVE SURVEILLANCE AND WATCHFUL WAITING AND RADICAL TREATMENT USING MACHINE LEARNING MODELS AMONG PROSTATE CANCER PATIENTS8
Re: Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, et al. J Urol Oncol. 2023;41(12):484.e7-484.e158
Cover 2 - Masthead8
RISK FACTORS FOR PROGRESSION IN PATIENTS WITH POST-BCG RECURRENT NMIBC8
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer8
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer8
Steroidogenesis in castration-resistant prostate cancer8
Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype8
Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma8
The relationship between BCG immunotherapy and oxidative stress parameters in patients with nonmuscle invasive bladder cancer8
Michael Droller: An appreciation, for his Festschrift 20248
DEVELOPMENT AND EXTERNAL VALIDATION OF A LOCAL PELVIC RECURRENCE RISK SCORE AFTER RADICAL CYSTECTOMY: IDENTIFYING THE IDEAL CANDIDATE FOR ADJUVANT RADIATION CLINICAL TRIALS8
CARCINOMA IN SITU AND URINARY CYTOLOGY AS AN INDICATOR OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BCG8
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma8
A mindful approach to complications: Brief review of the literature and practical guide for the surgeon8
A systematic review and meta-analysis evaluating the incidence, microbiological profile and risk factors associated with urinary tract infection after radical cystectomy7
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions7
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab7
Surgical templates for inguinal lymph node dissection in cN0 penile cancer: A comparative study7
HPV and urological cancers: Investigating renal and prostate cancer associations7
Prostatic adenocarcinoma: molecular underpinnings and treatment-related options7
Prevalence and management of castration-resistant prostate cancer of unknown metastatic status in the real-world setting: The AfroDiTA study7
A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010 – 20187
Prevalence of unnecessary kidney function exclusion criteria in urologic oncology clinical trials7
CYTOREDUCTIVE NEPHRECTOMY IS ASSOCIATED WITH IMPROVED SURVIVAL FOR SARCOMATOID METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED BEFORE OR AFTER SURGERY WITH IMMUNE CHECKPOINT INHIBITORS7
Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis7
Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy?7
Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis7
SEQUENTIAL ENDOLUMINAL GEMCITABINE AND CABAZITAXEL WITH SYSTEMIC PEMBROLIZUMAB FOR RECURRENT NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE UPPER AND LOWER URINARY TRACTS7
Bladder cancer patient and provider perspectives on smoking cessation7
Palliative and hospice care in prostate cancer: A scoping review7
Diagnostic accuracy of percutaneous renal mass biopsy in patients undergoing robot-assisted partial nephrectomy for localized renal cell carcinoma7
The fragility index of randomized controlled trials in advanced/metastatic renal cell cancer7
Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab7
Festschrift honoring Michael Droller7
GENE EXPRESSION DIFFERENCES AND PATHWAY ACTIVATION BY RACE IN ERG+ PROSTATE CANCERS: IMPLICATIONS FOR EQUITABLE CANCER CARE7
Second line salvage systemic therapy for advanced penile cancer7
Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 20187
The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer7
Comparison of oncologic outcomes following robot-assisted radical prostatectomy in high- and very high-risk prostate cancer based on the 2025 National Comprehensive Cancer Network risk stratification7
The association between perioperative activity levels and discharge outcomes after radical cystectomy7
Editorial Board7
The New WHO Category of “Molecularly Defined Renal Carcinomas”: Clinical and Diagnostic Features and Management Implications7
Prehabilitation: Cognitive considerations7
Deciphering the role of zingiber officinale phytochemicals for the treatment of prostate cancer: Interactions of phytochemicals with androgen receptor prostate cancer mutant H874Y ligand binding domai7
CONCORDANCE BETWEEN CLINICAL AND PATHOLOGIC STAGING OF T2A-B AND T3A RENAL CELL CARCINOMA: IMPLICATIONS FOR FUTURE PERIOPERATIVE CLINICAL TRIALS7
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES7
0.069633007049561